United States Patent 7,018,992: Estradiol Vaginal Tablet Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 7,018,992 covers low-dose vaginal estradiol tablets used to treat atrophic vaginitis, including 10 microgram tablets administered once or twice weekly and 5 microgram tablets administered twice weekly. The claims also address menopausal patients, treatment without progestogen, extended treatment periods, a specified excipient composition, film coating, systemic absorption, vaginal pH, and clinical outcomes.

The patent is associated with the low-dose Vagifem estradiol vaginal tablet technology. Its commercial importance was greatest for Novo Nordisk's Vagifem product and subsequent 10 microgram vaginal estradiol products. The patent's enforceable life has ended or is no longer a current barrier to generic entry, based on the public patent record and the age of the underlying priority filings. Current market risk is concentrated in later formulation, manufacturing, device, and product-specific patents rather than in the expired claims of Patent 7,018,992.

What does U.S. Patent 7,018,992 cover?

The patent claims methods of treating atrophic vaginitis by administering a low dose of estradiol vaginally in tablet form.

The central independent claims are:

Claim	Core subject matter
1	About 10 micrograms estradiol, administered vaginally once or twice weekly in tablet form
3	About 5 micrograms estradiol, administered vaginally twice weekly in tablet form

The claims are method-of-treatment claims rather than broad composition claims. They do not cover every estradiol vaginal product. They require a particular therapeutic use, route, dose range, dosing frequency, and dosage form.

Claim 1 is the principal commercial claim. A product would fall within its literal scope only if the relevant treatment protocol includes:

A patient with atrophic vaginitis;
Vaginal administration;
About 10 micrograms of estradiol;
Once- or twice-weekly administration; and
A tablet dosage form.

Claim 3 separately covers the 5 microgram, twice-weekly regimen. It does not depend on claim 1 and therefore creates an independent infringement pathway for a lower-dose vaginal estradiol tablet.

How do the dependent claims narrow Patent 7,018,992?

The dependent claims add patient, treatment-duration, formulation, pharmacokinetic, and clinical-result limitations.

Claim	Limitation	Scope effect
2	Patient is menopausal or post-menopausal	Limits the patient population
4	No progestogen is administered	Requires estrogen-only treatment under the claimed regimen
5	Treatment continues for more than two weeks	Excludes short courses
6	Treatment continues for more than one month	Further narrows duration
7	Treatment continues for more than three months	Requires prolonged treatment
8	Specific tablet core composition	Narrows to listed excipients and approximate quantities
9	Specific film coating	Narrows to hypromellose and macrogol 6000 coating
10	Undetectable systemic estradiol absorption	Adds a pharmacokinetic limitation
11	Vaginal pH below about 5.5	Adds a measurable treatment result
12	Symptom relief, improved atrophy, reduced pH, or improved cytologic maturation	Adds specified clinical or biological outcomes

Claims 8 and 9 are particularly important for product comparison. They identify a tablet composition containing hypromellose, lactose monohydrate, maize starch, and magnesium stearate, with a film coating based on hypromellose and polyethylene glycol 6000. These claims do not cover all low-dose estradiol tablets unless the accused product has the claimed composition or an equivalent formulation under applicable claim-construction and infringement principles.

What is the strongest claim in Patent 7,018,992?

Claim 1 is commercially broadest because it covers the principal 10 microgram once- or twice-weekly vaginal tablet regimen without requiring a specific excipient formula or clinical result.

Claim 3 is narrower in dose and frequency but remains commercially significant because it covers the 5 microgram twice-weekly regimen.

Claims 8 and 9 may be stronger against a product that copies the commercial tablet formulation, but they are easier to design around. A manufacturer could potentially avoid literal infringement by using different excipients, different quantities, a different coating, a softgel, a cream, a ring, or another delivery system.

Claims 10 through 12 may present proof issues. The terms "undetectable systemic absorption," "about 5.5," and treatment results such as "relief of vaginal symptoms" can require analytical, clinical, or claim-construction evidence. They may also raise questions about whether the limitation is measured by a specified assay, patient population, baseline value, or treatment period.

What is the patent's claim construction risk?

The most important construction issues are the following:

"About 10 micrograms"

"About" usually permits a range rather than requiring exactly 10.0 micrograms. The legally relevant range would depend on the specification, prosecution history, and intrinsic evidence. A 10 microgram labeled dose is the clearest target. Products labeled at materially different doses would present a weaker literal-infringement case under claim 1.

"Once or twice per week"

Claim 1 covers either once-weekly or twice-weekly administration. A regimen administered daily, every other day, monthly, or only during an induction phase may not satisfy this limitation literally, although treatment protocols must be analyzed as a whole.

"Tablet form"

The dosage form is a material limitation. Vaginal creams, inserts that are not legally characterized as tablets, rings, capsules, softgels, and other dosage forms are outside the literal scope of the tablet requirement. The doctrine of equivalents could create residual risk, but the tablet limitation reduces the reach of the claims.

"Undetectable systemic absorption"

Claim 10 is narrower than the independent claims. Low-dose vaginal estradiol products can produce measurable systemic estradiol concentrations depending on assay sensitivity, sampling time, mucosal condition, and treatment duration. A product with detectable systemic absorption would have a substantial noninfringement position under claim 10, although it could remain within claim 1.

"No progestogen"

Claim 4 requires that no progestogen be administered in the claimed treatment. The limitation may be relevant where a patient receives hormone therapy that includes a progestogen, but it does not change the scope of claim 1. A product can infringe claim 1 without infringing claim 4.

When did U.S. Patent 7,018,992 expire?

The patent issued March 28, 2006. Public patent records identify an earliest priority date in 1998 and show the patent as expired or no longer enforceable by its ordinary term. The likely nominal expiration fell around the end of the 20-year patent term calculated from the relevant nonprovisional filing or priority chain, with any patent-term adjustment affecting the final date.

Event	Date or status
Earliest priority chain	1998, according to public patent records
U.S. patent filing and prosecution	Late 1990s to early 2000s
Patent issued	March 28, 2006
Patent term	20-year term subject to applicable PTA rules
Current status	Expired or otherwise no longer an active exclusionary right in the public record

The precise terminal date should be taken from the USPTO Patent Center patent-term calculation and official maintenance records for litigation or freedom-to-operate work. The practical conclusion is unchanged: Patent 7,018,992 is not the principal current barrier to U.S. generic entry for low-dose vaginal estradiol tablets.

What was the FDA and Orange Book significance of Patent 7,018,992?

The patent was relevant to the Vagifem reference product, an estradiol vaginal insert marketed by Novo Nordisk. Vagifem was initially approved at 25 micrograms and later marketed in a 10 microgram strength. FDA labeling identifies vaginal estradiol as a local estrogen therapy for symptoms and signs of vulvar and vaginal atrophy associated with menopause.

The patent's relevance to the Orange Book depended on its listing against the applicable NDA and product strength. Orange Book listing is product-specific. A method-of-use patent may be listed when it claims an approved method of using the drug, but listing does not establish validity or infringement.

A generic applicant facing an unexpired listed method-of-use patent could submit:

Paragraph III certification, accepting that approval will wait until patent expiration;
Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed; or
A section viii statement, carving out a patented use from the proposed label where FDA rules permit.

For a method-of-use patent covering a vaginal estradiol dosing regimen, the practical strategy would depend on the proposed generic label, the exact listed use, and whether the applicant could omit the patented indication or dosing information without creating an impermissible carve-out.

Which companies challenged or competed with Vagifem?

The U.S. market developed around several distinct estradiol and non-estradiol vaginal products.

Product or technology	Company or sponsor	Dosage form	Main competitive issue
Vagifem	Novo Nordisk	Vaginal estradiol tablet/insert	Reference product for low-dose tablet therapy
Yuvafem	Generic sponsors, including end-market distributors	Vaginal estradiol insert	Generic equivalent to the 10 microgram product
Estrace vaginal cream	Allergan and generic sponsors	Cream	Different dosage form and formulation
Estring	Pfizer	Estradiol vaginal ring	Extended-release ring delivery
Imvexxy	TherapeuticsMD, later commercial partners	Estradiol softgel insert	Later softgel formulation and product-specific estate
Intrarosa	Endoceutics and later commercial partners	Prasterone vaginal insert	Non-estradiol alternative for dyspareunia

Yuvafem and other generic estradiol vaginal inserts created direct competition with the commercial product associated with the patent. Estrace cream and Estring compete clinically but do not generally practice the tablet limitations of claims 1 and 3.

What formulation patents are relevant to low-dose vaginal estradiol?

The patent landscape extends beyond Patent 7,018,992. Relevant patent categories include:

Vaginal tablet composition patents

These cover excipient selection, tablet hardness, disintegration, dissolution, content uniformity, and low-dose drug distribution. Such patents can be difficult to challenge if they are tied to manufacturing controls or product-specific specifications, but they can often be designed around by changing excipients or process parameters.

Film-coating patents

A coating based on hypromellose and polyethylene glycol may affect handling, stability, dissolution, and patient administration. Claims directed to exact coating materials and quantities have narrower commercial reach than claims directed to the therapeutic regimen.

Low-dose estradiol delivery patents

These address local delivery, reduced systemic exposure, controlled release, and treatment of vulvovaginal atrophy. They may cover tablets, inserts, rings, creams, gels, or softgels.

Manufacturing patents

Manufacturing protection can cover blending, granulation, compression, coating, packaging, moisture control, and content-uniformity methods. These rights may create supply-chain risk even when a generic product avoids a formulation patent.

Later product-specific patents

Products such as Imvexxy and newer vaginal hormone products may have later patents covering softgel composition, release characteristics, applicators, packaging, or specific dosing regimens. Those patents must be analyzed separately from the expired estate surrounding Vagifem.

How strong was the patent estate for Vagifem?

Patent 7,018,992 was commercially meaningful because it aligned with the low-dose vaginal tablet regimen that became central to Vagifem's product profile. Its strength came from the combination of:

Low-dose estradiol;
Vaginal administration;
Tablet dosage form;
Once- or twice-weekly dosing; and
Treatment of menopausal atrophic vaginitis.

Its limitations were equally significant. The claims were method claims, not broad composition claims. They did not cover every estradiol formulation or every route of administration. The 5 microgram claim covered a narrower dose and schedule. The formulation claims required specific ingredients and approximate amounts.

For current diligence, the estate's strength is low because the patent is expired or no longer enforceable. Historical strength depended on whether a generic label included the claimed regimen and whether the applicant could avoid the claims through a different dosage form, dosing schedule, or label carve-out.

What generic launch risks exist for low-dose vaginal estradiol?

The expired status of Patent 7,018,992 reduces direct patent risk for generic 5 and 10 microgram vaginal estradiol tablets. Residual risks can remain in four areas:

Later patents covering a product-specific formulation or manufacturing process;
FDA requirements for therapeutic equivalence and product quality;
Patent rights associated with a different reference product or dosage form;
Litigation over claim scope, equivalents, or product labeling.

A generic tablet that closely reproduces the historical Vagifem composition may face greater risk from later formulation or manufacturing patents than from Patent 7,018,992 itself. A cream, ring, softgel, or prasterone product generally presents a different patent analysis because it does not practice the tablet limitations.

What is the geographic coverage of Patent 7,018,992?

The patent is a United States right. It could block qualifying conduct involving U.S. manufacture, use, sale, offer for sale, or importation during its enforceable term. It does not automatically provide protection in Canada, Europe, Japan, or other markets.

The underlying invention may have corresponding foreign applications or granted patents, but foreign rights require separate review of national-phase filings, claim sets, term adjustments, supplementary protection certificates, lapse records, and local litigation. Expiration in the United States does not establish expiration elsewhere.

What litigation and settlement issues affected the patent?

Paragraph IV litigation is a potential pathway for any listed patent that remains unexpired when a generic application is filed. A lawsuit filed within the statutory period can trigger a 30-month stay of FDA approval, subject to the Hatch-Waxman framework and later court or regulatory events.

Publicly available product histories indicate that generic competition eventually entered the vaginal estradiol tablet market. The existence of generic entry is consistent with the expiration, invalidation, nonassertion, settlement, or successful design-around of relevant patent rights. It does not, by itself, establish the outcome of every patent dispute involving Vagifem or related products.

Patent 7,018,992 should therefore be treated as a historical Hatch-Waxman asset rather than a current litigation barrier. Any diligence report should distinguish this patent from later patents listed for specific strengths, formulations, or delivery systems.

How does Patent 7,018,992 compare with competing vaginal estrogen products?

Attribute	Vagifem/Yuvafem tablet	Estrace cream	Estring	Imvexxy
Active ingredient	Estradiol	Estradiol	Estradiol	Estradiol
Dosage form	Vaginal tablet/insert	Cream	Vaginal ring	Softgel insert
Typical dosing pattern	Low-dose intermittent administration	Cream regimen with applicator	Extended wear	Low-dose insert regimen
Patent 7,018,992 relevance	Directly relevant	Generally outside tablet limitation	Generally outside tablet limitation	Generally outside tablet limitation
Main patent risk	Tablet method, formulation, manufacturing	Cream formulation and applicator rights	Ring and release technology	Softgel and delivery technology
Generic pathway	ANDA or applicable abbreviated route	ANDA	Product-specific regulatory pathway	Product-specific formulation and regulatory pathway

The patent is most relevant to low-dose estradiol tablet products. It is not a broad patent on vaginal estrogen therapy.

Key Takeaways

U.S. Patent 7,018,992 claims vaginal treatment of atrophic vaginitis using low-dose estradiol tablets.
Claim 1 covers about 10 micrograms once or twice weekly.
Claim 3 covers about 5 micrograms twice weekly.
Claims 8 and 9 target a specific tablet core and film-coating formulation.
Claims 10 through 12 add pharmacokinetic, pH, symptom, and cytologic limitations.
The patent is a method-of-treatment patent, not a universal patent on estradiol or vaginal estrogen.
Its enforceable term has ended or is no longer a current U.S. exclusionary barrier.
Current generic-entry risk is more likely to arise from later formulation, manufacturing, delivery-system, or product-specific patents.
Vagifem/Yuvafem are the products most directly connected to the claimed technology.
Estrace cream, Estring, Imvexxy, and Intrarosa require separate patent and regulatory analyses.

FAQs

Does Patent 7,018,992 cover all 10 microgram estradiol products?

No. It requires vaginal administration in tablet form for treatment of atrophic vaginitis, with once- or twice-weekly administration. Other dosage forms and uses fall outside the literal scope of claim 1.

Can a generic avoid the patent by using a vaginal cream?

A cream would not literally satisfy the tablet limitation. It could still raise separate patent, regulatory, or labeling issues unrelated to Patent 7,018,992.

Does the patent cover systemic hormone replacement therapy?

No. The claims are directed to vaginal treatment of atrophic vaginitis using low-dose vaginal estradiol tablets. They do not broadly cover systemic estrogen therapy.

Are the excipient amounts in claim 8 exact?

The claim uses approximate quantities. The scope would depend on claim construction, the specification, prosecution history, and the accused product's formulation.

Is a 5 microgram product covered by claim 1?

Claim 1 is directed to about 10 micrograms. A 5 microgram product is addressed separately by claim 3, which requires twice-weekly vaginal administration in tablet form.

References

U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,018,992, methods of treating atrophic vaginitis with low-dose estradiol. https://patents.google.com/patent/US7018992
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (n.d.). Vagifem prescribing information. Novo Nordisk/FDA labeling materials.
U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug application patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submissions
U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Denmark	2000 01891	Dec 15, 2000
Denmark	2000 01892	Dec 15, 2000
Denmark	2000 01890	Dec 15, 2000

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	532521	⤷ Start Trial
Australia	2156702	⤷ Start Trial
Cyprus	1112542	⤷ Start Trial
Germany	10179223	⤷ Start Trial
Germany	20120246	⤷ Start Trial
Denmark	1343508	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,018,992

Summary for Patent: 7,018,992